Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
$5.57
-1.6%
$4.60
$2.01
$15.60
$10.17M5.343.46 million shs84,157 shs
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
$1.45
+1.4%
$1.63
$1.21
$2.55
$10.73M76.783,726 shs25,554 shs
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
$1.34
-2.2%
$1.22
$11.07
$33.08
$4.83M0.2340,215 shs30,358 shs
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
$1.86
+1.1%
$1.77
$1.32
$7.66
$9.51M2.42136,838 shs65,296 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
-1.59%-13.91%-4.30%+108.61%+27.75%
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
+1.40%+2.84%-10.49%-19.44%+9.85%
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
0.00%+1.52%+16.52%+14.53%-62.57%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
+1.09%+8.77%+27.40%+5.98%-97.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
0.1362 of 5 stars
0.03.00.00.01.10.00.0
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
3.0277 of 5 stars
3.55.00.00.00.03.30.6
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
0.9654 of 5 stars
0.03.00.00.02.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
0.00
N/AN/AN/A
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
3.00
Buy$18.001,141.38% Upside
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
0.00
N/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
$9.51M1.05N/AN/A$4.63 per share1.20
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
$400K27.19N/AN/A$1.23 per share1.18
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
N/AN/AN/AN/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
$620K15.51N/AN/A$4.30 per share0.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
-$1.60MN/A0.00N/A-22.85%-24.18%-20.14%8/13/2025 (Estimated)
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
-$8.98M-$1.47N/AN/AN/A-3,093.61%-129.47%-86.02%8/12/2025 (Estimated)
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
-$8.71M-$4.64N/AN/A-2,191.76%-72.81%-66.58%8/13/2025 (Estimated)

Latest DHAC, BGLC, BRTX, and MGRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
-$0.41N/AN/AN/A$0.34 millionN/A
5/15/2025Q1 2025
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
N/A-$0.03N/A-$0.03N/AN/A
5/15/2025Q1 2025
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A-$1.29N/A-$1.29N/A$0.11 million
5/14/2025Q1 2025
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
-$0.32-$0.56-$0.24-$0.64$0.38 million$0.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
N/AN/AN/AN/AN/A
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
N/AN/AN/AN/AN/A
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
N/AN/AN/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
N/A
4.19
3.44
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
N/A
2.24
2.24
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
N/AN/AN/A
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
N/A
0.12
0.12

Institutional Ownership

CompanyInstitutional Ownership
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
18.85%
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
69.38%
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
1.01%
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
56.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNexus Gene Lab Corp. stock logo
BGLC
BioNexus Gene Lab
301.80 million1.78 millionNot Optionable
Biorestorative Therapies, Inc. stock logo
BRTX
Biorestorative Therapies
77.50 million5.59 millionNot Optionable
Digital Health Acquisition Corp. stock logo
DHAC
Digital Health Acquisition
2,0213.60 million3.37 millionNot Optionable
Mangoceuticals, Inc. stock logo
MGRX
Mangoceuticals
35.17 million4.34 millionNot Optionable

Recent News About These Companies

Mangoceuticals President Tony Isaac Resigns
Mangoceuticals Acquires IP to Expand Product Line
Mangoceuticals Issues Bonus Shares to Leadership

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioNexus Gene Lab stock logo

BioNexus Gene Lab NASDAQ:BGLC

$5.57 -0.09 (-1.59%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$5.50 -0.07 (-1.26%)
As of 08/8/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Biorestorative Therapies stock logo

Biorestorative Therapies NASDAQ:BRTX

$1.45 +0.02 (+1.40%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$1.44 0.00 (-0.34%)
As of 08/8/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Digital Health Acquisition stock logo

Digital Health Acquisition NASDAQ:DHAC

$1.34 -0.03 (-2.19%)
As of 08/6/2025

Digital Health Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on technology and healthcare focused businesses. Digital Health Acquisition Corp. was incorporated in 2021 and is based in Boca Raton, Florida.

Mangoceuticals stock logo

Mangoceuticals NASDAQ:MGRX

$1.86 +0.02 (+1.09%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$1.80 -0.07 (-3.49%)
As of 08/8/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.